Castle Biosciences (CSTL) Inventory (2018 - 2026)

Castle Biosciences has reported Inventory for 9 years, with the latest figure at $10.6 million in Q2 2026.

• Quarterly Inventory rose 26.46% year-over-year to $10.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.6 million (up 26.46% YoY) and the FY2025 annual result came in at $10.3 million, up 26.05% from the prior year.
• Inventory improved to $10.6 million in Q2 2026 per CSTL's latest filing, from $10.5 million in the prior quarter.
• Over five years, Inventory peaked at $10.6 million in Q2 2026 and troughed at $2.4 million in Q1 2022.
• A 5-year average of $6.9 million and a median of $7.2 million in 2024 frame the typical range for Inventory.
• The sharpest annual moves came in 2023 and 2025: Inventory jumped 99.55% in 2023, then declined 10.41% in 2025.
• Over 5 years, Inventory stood at $4.0 million in 2022, then surged by 99.55% to $7.9 million in 2023, then gained by 2.43% to $8.1 million in 2024, then climbed by 26.05% to $10.3 million in 2025, then increased by 3.18% to $10.6 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $10.6 million, $10.5 million, and $10.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.